Amendment: Regulation 536/2014 (Medicinal products in UK/NI, CY, IE, MT)
This procedure concerns a temporary exception to rules on clinical trials for medicines. It allows certain investigational medicinal products to be made available in specific EU regions, including Northern Ireland, Cyprus, Ireland, and Malta.
This aims to ensure continued access to vital research medicines for patients in these areas, addressing potential supply chain disruptions and maintaining research continuity.
Documents
Amendment to Regulation (EU) No 536/2014
position · EN · 2026-05-02
Amendment to Regulation (EU) No 536/2014
proposal · EN · 2026-05-02
Amendment to Regulation (EU) No 536/2014
proposal · EN · 2026-05-02
Amendment to Regulation (EU) No 536/2014
proposal · EN · 2026-05-02
Amendment to Regulation (EU) No 536/2014
motion · EN · 2026-05-02
Amendment to Regulation (EU) No 536/2014
proposal · EN · 2026-05-02
Amendment to Regulation (EU) No 536/2014
proposal · EN · 2026-05-02
Amendment to Regulation (EU) No 536/2014
motion · EN · 2026-05-02
Amendment to Regulation (EU) No 536/2014
proposal · EN · 2026-05-02
Amendment to Regulation (EU) No 536/2014
motion · EN · 2026-05-02
Amendment to Regulation (EU) No 536/2014
motion · EN · 2026-05-02
Amendment to Regulation (EU) No 536/2014
motion · EN · 2026-05-02
Amendment to Regulation (EU) No 536/2014
motion · EN · 2026-05-02
Amendment to Regulation (EU) No 536/2014
proposal · EN · 2026-05-02
Amendment to Regulation (EU) No 536/2014
motion · EN · 2026-05-02
Amendment to Regulation (EU) No 536/2014
proposal · EN · 2026-05-02
Amendment to Regulation (EU) No 536/2014
proposal · EN · 2026-05-02